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higher incidence of ANA than the other beta-blockers in both male and female groups, but there were too few patients for this to be significant, and more patients are being sought. Most of the ANA-positive patients were also on treatment with methyldopa.
If the non-practolol beta-blockers are shown eventually to precipitate practolol-like reactions-even if all are associated with ANA-the assay will have little value as a screen for at-risk patients because of the many hypertensive patients who are ANA-positive. Most of these patients are taking methyldopa, which confirms the original observation of Breckenridge et al7 that this drug induces ANA in over 10% of patients. Apart from the occasional case of methyldopa-induced lupus, however, there seems to be no clinical risk with this drug in patients who develop ANA.
The effects of beta-blockers and other hypotensive agents on other autoantibodies will be the subject of a later report.
Introduction
Since the last outbreak of poliomyelitis in Scotland in 1962, at least eight poliovirus antibody surveys of different sections of the Scottish population have been carried out.1-4 Of these, four have disclosed potentially serious gaps in immunity. Because of the increasing number of immigrants in the United Kingdom we decided to extend our polio antibody surveillance to include these ethnic groups, which in Scotland are centred mainly in the Glasgow area. A study of the prevalence of various pathogenic organisms (parasites, bacteria, and hepatitis B) among the children of immigrants in Glasgow had already been conducted,5 so we took the opportunity to investigate the polio-immune status of these children, from whom serum specimens and detailed sociological information had already been obtained. Four ethnic groups were investigated-namely, Asians (from the Indian subcontinent), Africans (from various parts of Africa), Chinese (from Hong Kong), and Scots (included as a control group).
Subjects and methods
Of the sera taken from 500 children in the original study,5 only samples collected during 
Results
Seven of the 418 children-namely, three Asians, two Africans, one Chinese and one Scot-had no detectable antibody to any poliovirus type (table II) . None had received polio vaccine. Four were aged 4-7 months and were therefore too young for the polio vaccination programme, two were aged 1 year, and the Scot was 6 years old. After the completion of the study five of these seven children received a full course of polio vaccination, but the other two could not be traced. n So far as we are aware there are no reports on the poliovirus immunity of immigrants in the United Kingdom. Our results show that the children of immigrants in the Glasgow area do not constitute a health hazard with regard to poliomyelitis. This contrasts with reports from several other countries that children of immigrants predominate among the few residual cases of poliomyelitis, presumably because their parents may be less aware of the importance of immunisation than parents indigenous to the recipient, developed country. "8-1 The present poliovirus activity in the United Kingdom-12 cases so far during 197712-underlines the danger of complacency, which is becoming widespread owing to the dramatic reduction in the incidence of paralytic poliomyelitis since the introduction of polio vaccination programmes. This and the fact thit children commonly accompany their parents on intercontinental journeys increase the chance of non-immune travellers mixing with people from countries where poliomyelitis is still endemic; conversely, emigrants from such areas are flocking to countries of high industrial development.
Antibody surveys are a more reliable method of assessing immunity than either statistics of vaccine uptake or waiting for sporadic cases or outbreaks of paralytic poliomyelitis to signal a dangerous decline of immunity due to complacent undervaccination or to technical flaws in the vaccination procedure. Our investigations again emphasise the continued need for polio vaccination in the first year of life and the importance of revaccination, irrespective of ethnic group, at school entry and leaving age, when children can be "administratively captured."
Introduction
In Newcastle upon Tyne and several other centres an appreciable proportion of patients on regular haemodialysis develop an incapacitating type of bone disease characterised by bone pain and numerous fractures accompanied by proximal myopathy.' 2 Histological examination shows osteomalacia, with few active osteoblasts and little or no osteitis fibrosa. Serum concentrations of alkaline phosphatase and parathyroid hormone are often raised only slightly or not at all. This syndrome has failed to respond to treatment with calcium carbonate and phosphate binders,3 vitamin D2 or dihydrotachysterol,3 1a-hydroxycholecalciferol,4 5 or 1-25-dihydroxycholecalciferol,6 or the withdrawal of hepatic-enzyme-inducing drugs. A similar syndrome is sometimes seen in hypophosphataemic osteomalacia. 7 Some patients with hypophosphataemia and osteomalacia being treated with dialysis have responded to phosphate therapy,10 11 and it has been suggested that phosphate depletion may contribute to renal osteodystrophy.12 We carried out a prospective trial of phosphate-enriched dialysis fluid in 30 patients for 6-12 months to see whether we could treat or prevent osteomalacia by improving phosphate balance.
Patients and methods
Thirty patients were entered in the trial, 15 men and 15 women, aged between 18 and 60 (mean 41) years. All had been on regular haemodialysis for more than 6 months, using Meltec Multipoint 1 m2 dialysers and Lucas Mark II proportionating units, and dialysing 5-7 hours three times a week against a dialysate calcium of 1-6 mmol/l.
